Related Experiment Videos
Cisplatin plus etoposide in small cell lung cancer
P J Loehrer1, L H Einhorn, F A Greco
1Department of Medicine, Indiana University School of Medicine, Indianapolis 46223.
Seminars in Oncology
|June 1, 1988
Summary
Small cell lung cancer (SCLC) survival has improved with chemotherapy, particularly with cisplatin and etoposide. These agents offer better response rates and extended survival for SCLC patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Bronchogenic carcinoma, or lung cancer, is a leading cause of cancer-related death in the U.S.
- Small cell lung cancer (SCLC) accounts for 20-25% of lung cancer cases.
- SCLC has a poor prognosis, with a median survival of 2-4 months with supportive care alone.
Purpose of the Study:
- To review the role of cisplatin and etoposide in treating SCLC.
- To highlight advancements in SCLC treatment strategies.
Main Methods:
- Review of clinical trials and preclinical models for SCLC treatment.
- Focus on the efficacy of epipodophyllotoxins and platinum compounds.
Main Results:
- Combination chemotherapy has improved SCLC survival, with response rates of 60-80%.
- Median survival for treated SCLC patients increased to 10-14 months.
- Cisplatin and etoposide show significant single-agent activity in SCLC.
Conclusions:
- Chemotherapy, especially with cisplatin and etoposide, has significantly improved outcomes for SCLC patients.
- Further research into treatment strategies continues to enhance SCLC patient survival.